Maybe OHM knows. I sure dont. Any thoughts on h
Post# of 158054
(Total Views: 265)
Posted On: 10/19/2025 7:22:19 PM
Maybe OHM knows. I sure dont.
Any thoughts on how/if this might affect the current trial
"Impact of PD-L1 upregulation on immune checkpoint inhibitor efficacy in triple-negative breast cancer using a 4T1 murine model
https://pmc.ncbi.nlm.nih.gov/articles/PMC12221127/
Excerpt
..."To clarify this observation, the anti-PD-L1 effect was further tested by additionally including a group with medium-PD-L1-expression [PD-L1 O/E (Medium)], which had a lower PD-L1 expression level than the previously described overexpression group. The medium-level group was collected and confirmed by GFP sorting and immunoblotting (Fig. 3D and E). Of note, anti-PD-L1 treatment was most effective in the 4T1-PD-L1 O/E (Medium level) group and the treatment outcomes were similar to those observed in the 4T1-Ctl group; in some tumors, treatment exhibited improved antitumor effects (Fig. 3F and G). The improved antitumor effect in the 4T1-PD-L1 O/E (Medium level) group was also reflected in the final tumor weight measurements (Fig. 3H).
These findings demonstrate that PD-L1 expression is essential in determining the efficacy of anti-PD-L1 therapies. Excessive PD-L1 levels diminish treatment response, while the medium-level exhibited the greatest sensitivity to tumor treatment. This suggests that there may be an optimal PD-L1 expression range to maximize the effect of anti-PD-L1 therapy. This research emphasizes the need to further refine patient selection criteria for anti-PD-L1 therapy, as PD-L1 expression levels above a certain level alone may not be sufficient to predict treatment success"...
Any thoughts on how/if this might affect the current trial
"Impact of PD-L1 upregulation on immune checkpoint inhibitor efficacy in triple-negative breast cancer using a 4T1 murine model
https://pmc.ncbi.nlm.nih.gov/articles/PMC12221127/
Excerpt
..."To clarify this observation, the anti-PD-L1 effect was further tested by additionally including a group with medium-PD-L1-expression [PD-L1 O/E (Medium)], which had a lower PD-L1 expression level than the previously described overexpression group. The medium-level group was collected and confirmed by GFP sorting and immunoblotting (Fig. 3D and E). Of note, anti-PD-L1 treatment was most effective in the 4T1-PD-L1 O/E (Medium level) group and the treatment outcomes were similar to those observed in the 4T1-Ctl group; in some tumors, treatment exhibited improved antitumor effects (Fig. 3F and G). The improved antitumor effect in the 4T1-PD-L1 O/E (Medium level) group was also reflected in the final tumor weight measurements (Fig. 3H).
These findings demonstrate that PD-L1 expression is essential in determining the efficacy of anti-PD-L1 therapies. Excessive PD-L1 levels diminish treatment response, while the medium-level exhibited the greatest sensitivity to tumor treatment. This suggests that there may be an optimal PD-L1 expression range to maximize the effect of anti-PD-L1 therapy. This research emphasizes the need to further refine patient selection criteria for anti-PD-L1 therapy, as PD-L1 expression levels above a certain level alone may not be sufficient to predict treatment success"...
(2)
(0)